The platform generates, screens and produces in pre-industrial scale a wide range of recombinant antibodies and evaluates their efficiency and security in vitro and in vivo.
First class of drugs in oncology, monoclonal antibodies are also wildely used in inflammation diseases and the subject of the largest number of clinical trials. This success reflects the maturity of engineering and production technologies, which now allow producing these antibodies in recombinant form in mammalian cells in different formats.
Using its platform for high-speed generation and chimerization/humanization of antibodies, Mi-mAbs is able to generate antibodies in any format: whole antibodies or fragments of antibodies, chimeric, humanized or fully human antibodies, armed or un-armed antibodies.
Mi-mAbs designs antibodies with different mechanisms of action: biomodulatory antibodies (soluble ligand neutralization, blockage of receptors or membrane ligands, signal transduction), cytotoxic antibodies (ADCC or CDC) or immunoconjugates (ADC).
In practice, antibody isotypes determine their mechanism of action: human blocking antibodies are IgG4 or aglycosylated antibodies while cytotoxic antibodies are of isotype IgG1 in the human (able to recruit effectors in both human and mice) or mouse IgG2a (the major effector isotype in mice). Obtaining chimeric recombinant antibodies allows MI-mAbs to choose the isotype that achieves the desired pharmacological effect.
MI-mAbs has expression in CHO vectors that allow it to obtain all current isotypes (IgG1, IgG4) of humans and mice (IgG1, IgG2a, IgG2b). It is also able to express versions of mutated human IgG1 with increased ADCC properties, or antibodies without effector functions. In this context, it is implementing a process of high-speed chimerization bridging rodent immunization to pre-industrial chimeric antibody production in 14 weeks.